Granted Patent B1

US 12,415,868 · App. 18/892,093 · Granted Sep 16, 2025

Inventors: Cynthia Bamdad (Boston, MA); Benoit Smagghe (Honolulu, HI)

Assignee: MINERVA BIOTECHNOLOGIES CORPORATION

C07K16/40C07K2317/31C07K2317/33C07K2317/565C07K2317/622C07K2317/73C07K2317/76

Abstract

Claims (14)

1. A nucleic acid encoding a monoclonal antibody, a bispecific antibody, a bispecific T-cell engager, a Fab, or a single chain variable fragment antibody (scFv) comprising:

(a) a heavy chain variable region (HCV) comprising the sequence of any one of SEQ ID NOs: 1160, 1162, 1164, and 1181; and

a light chain variable region (LCV) comprising complementarity determining regions (CDRs) comprising a light chain CDR1 (LC-CDR1) comprising the sequence of SEQ ID NO: 434, an LC-CDR2 comprising the sequence of SEQ ID NO: 435, and an LC-CDR3 comprising the sequence of SEQ ID NO: 436; or

(b) an HCV comprising CDRs comprising a heavy chain CDR1 (HC-CDR1) comprising the sequence of SEQ ID NO: 429, an HC-CDR2 comprising the sequence of SEQ ID NO: 430, and an HC-CDR3 comprising the sequence of SEQ ID NO: 431; and

an LCV comprising the sequence of any one of SEQ ID NOs: 1166, 1168, 1170, 1183, 1203, and 1185;

wherein the monoclonal antibody, the bispecific antibody, the bispecific T-cell engager, the Fab, or the scFv binds to NME7.

2. The nucleic acid of claim 1 , wherein the HCV comprises the sequence of any one of SEQ ID NOs: 1160, 1162, 1164, and 1181; and the LCV comprises the sequence of any one of SEQ ID NOs: 1166, 1168, 1170, 1183, 1203, and 1185.

3. The nucleic acid of claim 1 , wherein the HCV comprises the sequence of SEQ ID NO: 1164, and the LCV comprises the sequence of any one of SEQ ID NOs: 1166, 1168, 1170, 1183, 1203, and 1185.

4. The nucleic acid of claim 1 , wherein the HCV comprises the sequence of any one of SEQ ID NOs: 1160, 1162, 1164, and 1181; and the LCV comprises the sequence of SEQ ID NO: 1185.

5. The nucleic acid of claim 1 , wherein the nucleic acid encodes the monoclonal antibody.

6. The nucleic acid of claim 1 , wherein the nucleic acid encodes the bispecific antibody.

7. The nucleic acid of claim 1 , wherein the nucleic acid encodes the bispecific T-cell engager.

8. The nucleic acid of claim 1 , wherein the nucleic acid encodes the scFv.

9. A cell comprising the nucleic acid of claim 1 .

Assignments (1)

Continuity (4)

References Cited (190)